Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug

Clinical Infectious Diseases

Volumn 30, Issue SUPPL. 2, 2000, Pages

  Lori, F ^a   Lisziewicz, J ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; HYDROXYUREA; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CELL CYCLE; CONFERENCE PAPER; DNA SYNTHESIS INHIBITION; DRUG ACTIVITY; DRUG INDICATION; DRUG POTENTIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS INHIBITION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; HYDROXYUREA; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

EID: 0034458322     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313851     Document Type: Conference Paper

References (36)

1. An overview of the clinical experience with hydroxyurea
2. Long-term toxicity/activity profile of 2′,3′-dideoxyinosine (didanosine) in AIDS or AIDS-related complex
3. Synergistic anti-human immunodeficiency virus type I effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes
4. The evolution of hydroxyurea therapy in chronic myelogenous leukemia
5. Hydroxyurea
6. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
7. Reversible inhibition of herpes simplex virus replication by hydroxyurea
8. Studies on the mechanism of replication of adenovirus DNA. 1. The effect of hydroxyurea
9. Effects of hydroxyurea on polyoma virus replication
10. Long-term cultures of HTLV-III-infected T cells: A model of cytopathology of T-cell depletion in AIDS
11. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure
12. HIV-1 replication is controlled at the level of T cell activation and proviral integration
13. Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication
14. Changes of deoxyribonucleotide triphosphate pools induced by hydroxyurea and their relation to DNA synthesis
15. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication
16. Anti-human immunodeficiency virus type I activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides
17. Metabolism and mechanism of antiviral action of purine and pyrimidine derivatives
18. The distribution, excretion, and metabolism of hydroxyurea-C14
19. Hydroxyurea in biologic fluids: Dose-concentration relationship
20. Increased activation of the combination of 3′-azido-3′-deoxythymidine and 2′-deoxy-3′-thiacytidine in the presence of hydroxyurea
21. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus
22. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance
23. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV-1 infection
24. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide
25. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor
26. Control of HIV despite the discontinuation of antiretroviral therapy
27. Reduction of HIV concentration during acute infection: Independence from a specific immune response
28. Population dynamics of HIV within an individual after treatment with zidovudine
29. Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV
30. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine
31. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine
32. Maintenance antiretroviral therapies in HIV-infected patients with undetectable plasma HIV RNA after triple-drug therapy
33. + T cell turnover
34. Immunology taught by viruses
35. T-cell-mediated immunopathology versus direct cytolysis by virus: Implications for HIV and AIDS
36. Title